Statement by Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on FDA’s Acceptance of Sandoz Biologics License Application for Filgrastim Under the New Biosimilar Pathway

Published Online: Thursday, July 24, 2014
Follow Pharmacy_Times:
PRESS RELEASE

“For the first time, the FDA has accepted a filing for an approval of a biosimilar drug, a major step toward access for Americans to safe, effective alternatives to costly brand biologic medicines.

Biosimilars have been successfully used in Europe and other markets for years. Filgrastim’s filing acceptance moves us closer to the day when U.S. patients that currently must rely on costly brand biologics for treatment will have more choices for the medicine that they need.

This approval represents a new frontier — not only for patients, but for our nation’s health system. Express Scripts projects that the United States would save $250 billion between 2014 and 2024 if filgrastim and 10 other biosimilars would enter the market.

We look forward to the integration of biosimilar therapies into the American health system, and witnessing the realization of the transformative potential of these innovative therapies.”
Related Articles
Express Scripts has been named the worst company to work for in the United States, while CVS ranked 12th on the same list.
For many pharmacy organizations, the Supreme Court King v. Burwell decision upholding the Affordable Care Act’s tax subsidies fended off potential confusion for patients concerning health insurance.
New study results suggest idarucizumab is an effective reversal agent for Boehringer Ingelheim's novel oral anticoagulant (NOAC), dabigatran (Pradaxa).
The FDA is currently reviewing Teva’s reslizumab treatment for adult and adolescent asthmatics with symptoms inadequately controlled by inhaled corticosteroid (ICS) regimens.
Latest Issues
$auto_registration$